Flagship Pioneering has appointed Guillaume Pfefer to serve as CEO-partner of the venture capital firm. He will also become CEO of Kintai Therapeutics, one of the Cambridge, MA-based firm’s portfolio companies.
Pfefer worked most recently at GlaxoSmithKline (NYSE: GSK), where he was senior vice president and global vaccine leader for Shingrix, the company’s shingles vaccine. He also previously served as president and CEO of Kala Pharmaceuticals (NASDAQ: KALA). His new appointment comes with additional changes to Kintai, a startup founded by Flagship and launched last year to research therapies that tap into the connections between the gut microbiome, the… Read more »
UNDERWRITERS AND PARTNERS
